Current Status and Evaluation of Randomized Clinical Trials of Traditional Chinese Medicine in the Treatment of Cardiovascular Diseases

Xi Guo, Xiaojun Chen, Jinlan Chen, Zhiping Tan, Yifeng Yang, Hong ZhangEvidence-based 2022 · DOI

TL;DR

This review systematically analyzes randomized controlled trials (RCTs) of Traditional Chinese Medicine (TCM) for cardiovascular diseases (CVDs). It highlights that while TCM shows promise in managing CVD risk factors and symptoms, robust evidence for reducing major adverse cardiovascular events and mortality is still lacking, underscoring the need for more standardized and large-scale research.

What Problem Does This Paper Address?

Cardiovascular diseases (CVDs) are a leading cause of death globally, and while Traditional Chinese Medicine (TCM) has a long history of use in China, its efficacy and safety in treating CVDs are not well-established in Western medicine's evidence-based framework. The core problem is the lack of high-quality, standardized randomized controlled trials (RCTs) that can provide robust evidence for TCM's role in CVD prevention and treatment, hindering its integration into clinical guidelines. This paper aims to bridge this gap by reviewing the existing RCT landscape for TCM in CVDs.

Methods

The authors conducted a comprehensive literature search across seven Chinese and English electronic databases, as well as clinical trial registries. They employed a specific search algorithm combining terms for TCM, CVDs, and randomized controlled trials. Inclusion criteria focused on RCTs with a minimum sample size of 50, interventions involving various TCM modalities (herbal medicine, acupuncture, etc.), and clear diagnostic criteria. Exclusion criteria included non-randomized or non-blinded trials, studies with low Jadad scores, and those lacking objective laboratory examinations. The review then categorized and analyzed the included studies based on the CVD aspect being treated: risk factors (hypertension, dyslipidemia), atherosclerotic cardiovascular disease (ASCVD), and chronic heart failure.

Datasets

Not discussed in the paper. The paper is a review of existing literature and does not introduce or utilize new datasets.

Key Insights and Ideas

  • TCM Shows Promise for Risk Factors and Symptoms: The review consistently finds that various TCM interventions demonstrate positive effects on managing CVD risk factors like hypertension and dyslipidemia, and on alleviating symptoms in patients with ASCVD and chronic heart failure.
  • Evidence for Major Event Reduction is Scarce: Despite improvements in symptoms and risk markers, there's a significant lack of evidence showing that TCM interventions can reduce the incidence of major adverse cardiovascular events (MACEs), mortality, or rehospitalization.
  • Intervention Heterogeneity is a Challenge: The vast array of TCM interventions, often used in combination with Western medicine or as multi-component therapies, makes it difficult to isolate the specific effects of individual TCM treatments.
  • Outcome Measurement Inconsistency: A major limitation identified is the lack of standardized primary and secondary outcome measures across studies, with many relying on surrogate markers or symptom scores rather than hard clinical endpoints.
  • Safety Reporting Needs Improvement: While most studies report minimal adverse events, the safety outcome reports are often simple and lack detailed descriptions of potential drug interactions or long-term safety data.

Key Results

The review identified 30 relevant RCTs, including 16 in English and 14 in Chinese.

  • Hypertension: Several TCM interventions, such as Gastrodia-Uncaria granules and Tiankuijiangya tablets, showed significant effects in reducing blood pressure, with generally good safety profiles.
  • Dyslipidemia: TCM treatments like Jiangzhi Tongluo soft capsules and Xuezhitong capsules demonstrated efficacy in reducing serum lipids (TG, LDL-C, TC) when used as adjuncts to standard therapy.
  • ASCVD: TCM interventions like Xinling Wan pill, Shexiang Baoxin pill, and Xinyue capsule showed benefits in improving symptoms, reducing nitroglycerin use, and potentially reducing MACEs in some studies, though evidence for reducing hard endpoints was mixed.
  • Chronic Heart Failure: TCM treatments such as Qishen Yiqi dripping pills, Qiliqiangxin capsules, and Shenmai injection were found to improve symptoms, quality of life, and cardiac function (e.g., LVEF, 6-minute walk distance), but did not consistently show a reduction in acute heart failure events or rehospitalization.

Limitations and Future Work

The authors acknowledge several limitations:

  • Intervention Complexity: The diverse nature of TCM interventions and the frequent use of multi-component or add-on therapies make it challenging to attribute effects to specific TCM agents.
  • Outcome Measure Standardization: A significant issue is the lack of clear, consistent primary and secondary outcome measures, leading to difficulties in comparing results and drawing definitive conclusions. Many studies rely on surrogate markers or symptom scores, which may not fully reflect clinical significance.
  • Safety Reporting: The reporting of safety outcomes is often basic, lacking detailed data on drug interactions and long-term safety profiles.

Future work should focus on:

  • Rigorous, Large-Scale RCTs: Conducting more well-designed, large-scale RCTs with standardized protocols is crucial.
  • Focus on Hard Endpoints: Future research should prioritize evaluating the impact of TCM on major adverse cardiovascular events, mortality, and rehospitalization rates.
  • Clearer Outcome Measures: Establishing and consistently using appropriate clinical outcome measures that are clinically meaningful is essential for accurate evaluation.
  • Detailed Safety Reporting: Comprehensive reporting of safety data, including potential interactions and long-term effects, is needed.

Summary updated

Abstract

Traditional Chinese medicine has long been applied to various diseases in China for a few thousand years. In recent years, its market has gradually developed from Asian countries to Western countries. At present, due to the lack of evidence-based medicine research, the effect of traditional Chinese medicine on the prevention and treatment of cardiovascular disease remains unclear. In evaluating the efficacy and safety of drugs, randomized controlled clinical trials (RCTs) are recognized as the gold standard for testing the effectiveness and safety of treatments and could offer the best evidence for the formulation of clinical treatment guidelines. Although traditional Chinese medicine has long been used to treat cardiovascular diseases, the research on the application of RCT to test the combination of traditional Chinese and Western medicine therapy or single traditional Chinese medicine therapy started late, and the number is comparably small. In order to summarize and objectively evaluate the research results of integrated traditional Chinese and Western medicine in intervention of cardiovascular diseases, we reviewed the literature of RCTs in this field by searching some Chinese and English databases and put forward some suggestions for the future development and research of traditional Chinese medicine.
BibTeX
@inproceedings{guo2022current,
  author = {Xi Guo and Xiaojun Chen and Jinlan Chen and Zhiping Tan and Yifeng Yang and Hong Zhang},
  title = {{Current Status and Evaluation of Randomized Clinical Trials of Traditional Chinese Medicine in the Treatment of Cardiovascular Diseases}},
  booktitle = {Evidence-based},
  year = {2022},
  doi = {10.1155/2022/6181862},
}
Figure